Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Cue Biopharma (Nasdaq:CUE), a clinical-stage therapeutics company developing therapies for immunological disorders, announced that president and CEO Shao-Lee Lin will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City.
A live audio webcast, replay, and 90-day archive will be available on Cue Biopharma’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CUE
In the May 22 session, CUE gained 6.82%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.5% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 2026 earnings | Positive | -9.2% | Higher collaboration revenue, narrower net loss, but shares fell post-release. |
| May 07 | Inducement grants | Neutral | -2.0% | Equity awards to new CEO and hires under Nasdaq inducement rule. |
| Apr 30 | Private placement | Positive | +106.4% | $30M private placement via warrants to fund pipeline and Ascendant-221. |
| Apr 30 | Pipeline license | Positive | +106.4% | Exclusive global license for Phase 2 anti-IgE Ascendant-221, milestones, royalties. |
| Apr 30 | Leadership change | Positive | +106.4% | Appointment of Shao-Lee Lin as CEO to lead clinical-stage transition. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions around the April 30 licensing, financing, and leadership transition cluster, contrasted with negative reactions to subsequent earnings and inducement grant announcements.
Over the last few months, Cue Biopharma has transformed around key events. On Apr 30, the company announced an exclusive Ascendant-221 license, a $30 million private placement, and the appointment of Shao-Lee Lin as CEO, with shares reacting about +106.38%. In early May, inducement grants and Q1 2026 results, including higher collaboration revenue and reduced net loss, saw negative price reactions. Today’s conference appearance update follows this period of strategic, financing, and leadership changes.
Key Terms
immunological disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City.
A live audio webcast and replay of the presentation will be available through Cue Biopharma’s Investor Relations website. The webcast will be archived for 90 days.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor and Media Contact
Agnes Lee
Chief Officer of Public and Investor Relations
Marie Campinell
Senior Director, Corporate Communications
ir@cuebio.com
Cue Biopharma, Inc.
